Orgenesis, a pioneering, global biotech company committed to lowering costs, accelerating commercialization, and transforming the delivery of cell and gene therapies (CGTs), announces it has entered into an agreement to acquire the assets of Tamir Bio, including ranpirnase, TamirBio’s broad spectrum anti-viral platform.
Orgenesis Announces Agreement to Acquire TamirBio
